Chromocell Hits Stock Markets Following $6.6M IPO
Clinical-stage biotechnology company Chromocell Therapeutics Corp. began trading publicly on Friday after raising $6.6 million in its initial public offering, becoming the latest in a flurry of biotech IPOs....To view the full article, register now.
Already a subscriber? Click here to view full article